Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

Neurological Sciences

Volumn 32, Issue 2, 2011, Pages 351-358

  Ghezzi, A ^a   Grimaldi, L M E ^b   Marrosu, M G ^c   Pozzilli, C ^d   Comi, G ^e   Bertolotto, A ^f   Trojano, M ^g   Gallo, P ^h   Capra, R ⁱ   Centonze, D ^j   Millefiorini, E ^k   Sotgiu, S ^l   Brescia Morra, V ^m   Amato, M P ⁿ   Lugaresi, A ^o   Mancardi, G ^p   Caputo, D ^q   Montanari, E ^r   Provinciali, L ^s   Durelli, L ^t   Bergamaschi, R ^u   Bellantonio, P ^v   Tola, M R ^w   Cottone, S ^b   Savettieri, G ^x   Tedeschi, G ^y   more..

^a Ospedale di Gallarate   (Italy)

^b AO Villa Sofia CTO   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF BARI   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ Centro di Riferimento per la Sclerosi Multipla   (Italy)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l UNIVERSITY OF SASSARI   (Italy)

^m UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o UNIVERSITY OF CHIETI   (Italy)

^p UNIVERSITY OF GENOA   (Italy)

^q IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^r UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^s UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^t SAN LUIGI GONZAGA HOSPITAL   (Italy)

^u C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^v IRCCS NEUROMED   (Italy)

^w UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^x UNIVERSITY OF PALERMO   (Italy)

^y SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

IRIS; Multiple sclerosis; Natalizumab; PML

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; BETA INTERFERON; CIDOFOVIR; CORTISONE; CYCLOPHOSPHAMIDE; DRUG ANTIBODY; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MEFLOQUINE; METHOTREXATE; METHYLPREDNISOLONE; MIRTAZAPINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY;

ARTICLE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MEDICAL SOCIETY; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROLOGY; PATIENT MONITORING; PATIENT SELECTION; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; RISK BENEFIT ANALYSIS;

ANTIBODIES, MONOCLONAL; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 79952902537     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-010-0469-0     Document Type: Article

References (35)

1. GP Rice HP Hartung PA Calabresi 2005 Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale Neurology 64 1336 1342 15851719 1:CAS:528:DC%2BD2MXivFOgt7w%3D (Pubitemid 40570497)
2. M Khademi L Bornsen F Rafatnia, et al. 2009 The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers Eur J Neurol 16 528 536 19220425 10.1111/j.1468-1331.2009.02532.x 1:STN:280:DC%2BD1M3mtVKitw%3D%3D
3. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
4. RA Rudick WH Stuart PA Calabresi, et al. 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 911 923 16510745 10.1056/NEJMoa044396 1:CAS:528:DC%2BD28XitVertLw%3D
5. A Langer-Gould SW Atlas AJ Green, et al. 2005 Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 375 381 15947078 10.1056/NEJMoa051847 1:CAS:528:DC%2BD2MXms1Kntrc%3D (Pubitemid 41132342)
6. BK Kleinschmidt-DeMasters KL Tyler 2005 Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 369 374 15947079 10.1056/NEJMoa051782 1:CAS:528:DC%2BD2MXms1KntrY%3D (Pubitemid 41132341)
7. G Van Assche M Van Ranst R Sciot, et al. 2005 Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 362 368 15947080 10.1056/NEJMoa051586 (Pubitemid 41132340)
8. TA Yousry EO Major C Ryschkewitsch, et al. 2006 Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 924 933 16510746 10.1056/NEJMoa054693 1:CAS:528:DC%2BD28XitVertLs%3D
9. Commissione delle Comunità Europee, decisione della commisione del 27-VI-2006 che accorda a norma del regolamento (CE) n. 726/2004 del Parlamento europeo e del Consiglio l'autorizzazione ad immettere in commercio il "Tysabri-natalizumab", un medicinale per uso umano
10. Food and Drug Administration News Release (2010) http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2006/ucm108662.htm. Accessed 29 Sept 2010
11. Agenzia Italiana del Farmaco, determinazione del 7 dicembre (2006) http://aifa-neuro.agenziafarmaco.it/tysabri.pdf. Accessed 29 Sept 2010
12. Mancardi GL, Tedeschi G, Amato MP et al (2010) Three years of experience: the Italian registry and safety data update. Neurol Sci. 20 July 2010 [Epub ahead of print]
13. DB Clifford A De Luca DM Simpson, et al. 2010 Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 438 446 20298967 10.1016/S1474-4422(10) 70028-4 1:CAS:528:DC%2BC3cXltF2ktLg%3D
14. Biogen Idec (2010) http://www.biogenidec.ch/. Accessed 29 Sept 2010
15. N Putzki O Yaldizli R Bühler, et al. 2010 Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland Eur Neurol 63 101 106 20090344 10.1159/000276400 1:CAS:528:DC%2BC3cXhvFGht7g%3D
16. O Outteryck JC Ongagna H Zéphir, et al. 2010 Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice J Neurol 257 207 211 19711113 10.1007/s00415-009-5294-0
17. Belachew S, Phan-Ba R, Bartholomé E et al (2010) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. doi: 10.1111/j.1468-1331.2010.03112.x
18. Piehl F, Holmén C, Hillert J et al (2010) Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. doi: 10.1007/s10072-010-0345-y
19. Sangalli F, Moiola L, Bucello S et al (2010) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. doi: 10.1007/s10072-010-0344-z
20. Prosperini L, Borriello G, Fubelli F et al (2010) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci. doi: 10.1007/s10072-010-0348-8
21. DS Goodin 1991 The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review Neurology 41 980 985 2067661 1:STN:280:DyaK3M3ps1WmsA%3D%3D
22. Martinelli V, Bergamaschi R, Bellantonio P et al (2010) Incidence of acute myeloid leukemia and related mortality in Italian MS patients treated with mitoxantrone. Mult Scler (Suppl 10): P480
23. JJ Marriott JM Miyasaki G Gronseth, et al. 2010 Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology Assessment subcommittee of the American Academy of Neurology Neurology 74 1463 1470 20439849 10.1212/WNL.0b013e3181dc1ae0 1:CAS:528:DC%2BC3cXls1Cktb4%3D
24. A Ghezzi C Pozzilli LM Grimaldi, et al. 2010 Safety and efficacy of natalizumab in children with multiple sclerosis Neurology 75 912 917 20820002 10.1212/WNL.0b013e3181f11daf 1:CAS:528:DC%2BC3cXhtFaitrvI
25. L Gorelik M Lerner S Bixler, et al. 2010 Anti-JC virus antibodies: implications for PML risk stratification Ann Neurol 68 295 303 20737510 10.1002/ana.22128
26. Cristiano LM, Bozic C, Kooijmans M (2010) Preliminary evaluation of pregnancy outcomes from the TYSABRI (natalizumab) pregnancy exposure registry.In: Poster P01.185 presented at the 62nd annual meeting of the American Academy of Neurology, Toronto
27. L Kappos D Bates HP Hartung, et al. 2007 Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Lancet Neurol 6 431 441 17434098 10.1016/S1474-4422(07)70078-9 (Pubitemid 46551850)
28. BO Khatri S Man G Giovannoni, et al. 2009 Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function Neurology 72 402 409 19188571 10.1212/01.wnl.0000341766.59028.9d 1:CAS:528: DC%2BD1MXhtVClu70%3D
29. Schröder A, Lee DH, Hellwig K et al (2010) successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol. doi: 10.1001/archneurol.2010.157
30. W Wenning A Haghikia J Laubenberger, et al. 2009 Treatment of progressive multifocal leukoencephalopathy associated with natalizumab N Engl J Med 361 1075 1080 19741228 10.1056/NEJMoa0810257 1:CAS:528:DC%2BD1MXhtFartr3M
31. M McCarthy A Nath 2010 Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS) Curr Neurol Neurosci Rep 10 467 475 20697980 10.1007/s11910-010-0138-y
32. Grimaldi LME et al (2010) An MRI study of the therapeutic window in natalizumab treated MS patients (submitted)
33. MM Vellinga JA Castelijns F Barkhof, et al. 2008 Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients Neurology 70 13 Pt 2 1150 1151 17872364 1:STN:280:DC%2BD1c3gt1Wnsw%3D%3D (Pubitemid 351464749)
34. O Stüve PD Cravens EM Frohman, et al. 2009 Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy Neurology 72 396 401 18987352 10.1212/01.wnl.0000327341.89587.76
35. J Killestein A Vennegoor EM Strijbis, et al. 2010 Natalizumab drug holiday in multiple sclerosis: poorly tolerated Ann Neurol 68 392 395 20661928 10.1002/ana.22074